KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomePreferred Dividend PaymentsProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Palvella Therapeutics (PVLA) Net Income towards Common Stockholders (2016 - 2026)

Palvella Therapeutics has reported Net Income towards Common Stockholders over the past 10 years, most recently at -$11.9 million for Q3 2022.

  • Quarterly Net Income towards Common Stockholders rose 37.25% to -$11.9 million in Q3 2022 from the year-ago period, while the trailing twelve-month figure was -$31.6 million through Dec 2022, up 39.06% year-over-year, with the annual reading at $64000.0 for FY2025, 100.37% up from the prior year.
  • Net Income towards Common Stockholders was -$11.9 million for Q3 2022 at Palvella Therapeutics, up from -$12.2 million in the prior quarter.
  • Over five years, Net Income towards Common Stockholders peaked at -$203000.0 in Q2 2018 and troughed at -$19.0 million in Q3 2021.
  • The 5-year median for Net Income towards Common Stockholders is -$10.3 million (2019), against an average of -$8.9 million.
  • Year-over-year, Net Income towards Common Stockholders soared 97.99% in 2018 and then tumbled 5692.12% in 2019.
  • A 5-year view of Net Income towards Common Stockholders shows it stood at -$11.7 million in 2018, then skyrocketed by 93.4% to -$771000.0 in 2019, then tumbled by 1508.69% to -$12.4 million in 2020, then grew by 11.27% to -$11.0 million in 2021, then decreased by 8.38% to -$11.9 million in 2022.
  • Per Business Quant, the three most recent readings for PVLA's Net Income towards Common Stockholders are -$11.9 million (Q3 2022), -$12.2 million (Q2 2022), and -$7.5 million (Q1 2022).